483
Fujifilm CorporationFujifilm Corporation – FDA 483, Jul 13, 2018
Record Details
An FDA inspection of Fujifilm Corporation, a medical device manufacturer in Ashigarakami-gun, Kanagawa, Japan, revealed significant deficiencies in its complaint handling procedures for the ASPIRE Cristalle with Digital Breast Tomosynthesis (DBT) Option. The firm failed to adequately document complaints, ensure completion of corrective actions, and identify root causes for reported issues. These findings indicate a lack of robust controls in the firm's quality system for managing complaints.
View Company Profile
ID · e3852ef6-6cd1-403b-9ba1-eeca4150adb4
Other documents for Fujifilm Corporation
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.